Search This Blog

Friday, March 13, 2026

Allogene extends cash runway to Q1 2028, beats Q4 estimates ahead of pivotal ALPHA3, ALLO-329 readouts

 


  • 2026 is framed as a proof year with two major data catalysts in oncology and autoimmune.
  • ALPHA3 interim MRD data and futility analysis in April 2026 aim for 25–30% absolute MRD clearance delta vs observation.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)